Pre Next

PDF Download

[1] WANG Ying TANG Xiaonan WANG Huiyi CUI Yanhui CAO Fei KANG Xiaohong,.Effect of Cinobufagin Capsule Combined with Gefitinib on Clinical Efficacy and Serum miR221 Expression in Patients with Advanced Lung Cancer [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2021, (06): 84-88. [doi: 10.13424/j.cnki.jsctcm.2021.06.017]

Copy

Effect of Cinobufagin Capsule Combined with Gefitinib on Clinical Efficacy and Serum miR221 Expression in Patients with Advanced Lung Cancer

Journal of Shaanxi University of Traditional Chinese Medicine[ISSN: 2096-1340/ CN: 61-1501/R] Volumes & Issues: 2021 06 pagination: 84-88 Column: Publication date: 2021-11-30

Article number:: 2096-1340(2021)06-0084-05

Author(s):: WANG Ying1 TANG Xiaonan1 WANG Huiyi1 CUI Yanhui1 CAO Fei2 KANG Xiaohong1; 1. Department of Oncology，The First Affiliated Hospital of Xinxiang Medical College，Henan Xinxiang 453100,China;
2. Cancer Research Center of Pingdingshan First Peoples Hospital，Henan Pingdingshan 467000，China

Keywords:: Key words： Lung cancer; Cinobufagin capsule; Gefitinib; miR-221; Drug resistance

ZTFLH:: R734.2

DOI:: 10.13424/j.cnki.jsctcm.2021.06.017

Code:: A

References:

［1］Siegel RL，Miller KD，Jemal A.Cancer statistics，2020［J］.CA Cancer J Clin，2020，70(1):7-30.
［2］Ohashi K，Maruvka YE，Michor F，et al.Epidermal growth factor receptor tyrosine kinase inhibitorresistant disease［J］.J Clin Oncol，2013，31(8):1070-1080.
［3］Maione P，Sacco PC，Sgambato A，et al.Overcoming resistance to targeted therapies in NSCLC:current approaches and clinical application［J］.Ther AdvMed Oncol，2015,7(5):263-273.
［4］Popat S.Osimertinib as First-Line Treatment in EGFRMutated NonSmallCell Lung Cancer［J］.N Engl J Med，2018,378(2):192-193.
［5］原发性肺癌诊疗规范(2018年版)［J］.肿瘤综合治疗电子杂志,2019,5(3):100-120.
［6］Goldstraw P，Chansky K，Crowley J，et al.The IASLC Lung Cancer Staging Project:Proposals for Revision of the TNM Stage Groupings in the Forthcoming(Eighth) Edition of the TNM Classification for Lung Cancer［J］.J Thorac Oncol,2016,11(1):39-51.
［7］Eisenhauer EA,Therasse P，Bogaerts J，et al.New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1)［J］，Eur J Cancer,2009,45(2):228-247.
［8］Shimizu T，Saijo N.Common toxicity criteria：version 2.0，an improved reference for grading the adverse reaction of cancer treatment［J］.Nihon Rinsho，2003,61(6):937-942.
［9］樊李瀛，衡立松，段虹昊，等.骨肉瘤患者肿瘤组织中PLOD2基因表达水平及其对肿瘤细胞迁移/侵袭的影响［J］.临床和实验医学杂志，2019，18(24):2589-2593.
［10］朱必胜,田红岸,舒诚荣,等.华蟾素胶囊联合放疗治疗晚期胰腺癌的临床效果观察［J］.中国医药，2020，15(5):749-752.
［11］李现忠.华蟾素胶囊联合化疗对晚期非小细胞肺癌患者的疗效［J］.实用中西医结合临床，2020,20(3):47-48.
［12］陈进宝,殷佩浩.蟾毒灵抗肿瘤作用分子机制的研究进展［J］.河北中医,2019,41(1):140-145.
［13］Kang XH，Xu ZY，Gong YB，et al.Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis［J］.Evidence-Based Complementary and Alternative Medicine，2013:243859.
［14］康小红,路平,崔艳慧,等.蟾毒灵对肝细胞生长因子诱导的阿法替尼耐药的逆转作用［J］.中华肿瘤杂志,2015,37(7):490-496.
［15］Liu M，Liu J，Wang L，et al.Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival［J］.PLoS One,2014,（9）:e109347.
［16］Zheng Q，Peskoe SB，Ribas J，et al.Investigation of miR-21，miR-141,and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy［J］.Prostate,2014,（74）:1655-1662.
［17］高园园，康小红，王颖，等.微RNA-221诱导PC-9肺癌细胞对吉非替尼的耐药机制［J］.中华医学杂志，2018,98(42):3447-3452.

Memo

基金项目：国家自然科学基金项目（82074268，81503414，81874392，82074231）；河南省医学科技攻关项目（SB201903014，LHGJ20191263）

Last Update: 2021-11-25